Endogenous Mechanisms of Inactivation of the Endothelium Tumor

NCT ID: NCT03667612

Last Updated: 2018-09-12

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 70 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-01-31
• Study Completion Date: 2019-10-31

Brief Summary

The role of immunity in the development of cancers, and the associated escape mechanisms, have attracted renewed interest since the publication of tests testing immunological checkpoint inhibitors. One of the steps in the probably least studied immunological response is the penetration of immunocompetent cells within the tumor across the vascular barrier. This infiltration is suggested as a prognostic and predictive marker of treatment response, particularly in triple negative HER2 (Human Epidermal Growth Factor Receptor-2) overexpressing breast cancers. The methods of evaluating these infiltrates are complex and have been the subject of recommendations.

A better understanding of the mechanisms of infiltration of immunity cells within tumors will certainly help to better understand the impact of cancer treatments and develop new therapeutic strategies.

It is this issue of vascular endothelium that Dr. Soncin's team is developing as part of an INCa (Institut National du cancer) project. The egfl7 / VE-statin (vascular endothelial-statin) gene is thought to be involved in transendothelial passage of immune cells from vascular lumen to tumor. Its expression has already been studied in a series of breast cancers. Other markers of endothelial activation are currently being identified.

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al. that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation

Detailed Description

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al., that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation

Conditions

Breast Cancer; Colon Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Patients with breast cancer

• Patients clinical data collection
• Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres
• Realization of tumor samples series of cuts and paraffin shavings for:

• Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
• Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)
• Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)
• Characterization of lymphocyte populations
• Measurement of the endothelial cell density, the lymphatic endothelium and the "High Endothelial Venules"

No interventions assigned to this group

Patients with colorectal cancer

• Patients clinical data collection
• Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments
• Realization of series of cuts and paraffin shavings of the tumor samples for:

• Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
• Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)
• Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)
• Characterization of lymphocyte populations
• Measurement of the endothelial cell density, the lymphatic endothelium and the "High Endothelial Venules"

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Men and women aged 18 and over
• Confirmed histological diagnosis of breast carcinoma at localized or metastatic stage or colorectal cancer
• Treated at the Oscar Lambret Center or the Henri Becquerel Center between 1/1/2005 and 31/12/2007
• Having undergone surgery for excision of the primary tumor and / or a metastasis
• resected specimen available
• Patients who gave their consent

Exclusion Criteria

• History of other cancers
• Breast or colic tumors with other histological profiles
• Patient treated for breast or colonic recurrence

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut de Biologie de Lille

OTHER

Sponsor Role: collaborator

Centre Oscar Lambret

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Géraldine Lauridant, MD

Role: PRINCIPAL_INVESTIGATOR

Centre oscar Lambret de Lille

Locations

Centre Oscar Lambret

Lille, , France

Centre Henri Becquerel

Rouen, , France

Countries

France

Other Identifiers

BreastIls-1605

Identifier Type: -

Identifier Source: org_study_id